NCT00390091View on ClinicalTrials.gov

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2006

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

abetimus sodium (LJP 394)

Trial Locations (2)

16635

Altoona Center for Clinical Research, Duncansville

90048

Wallace Rheumatic Study Center, Los Angeles

Sponsors
All Listed Sponsors
lead

La Jolla Pharmaceutical Company

INDUSTRY

NCT00390091 - Study of LJP 394 (Abetimus Sodium) in Lupus Patients | Biotech Hunter | Biotech Hunter